Christopher L Reid

US Patent:

20080206202, Aug 28, 2008

Filed:

Oct 29, 2007

Appl. No.:

11/927399

Inventors:

Christopher Reid - Long Beach CA, US
Svetlana Pack - Gaithersburg MD, US

International Classification:

A61K 48/00
C12N 5/06

US Classification:

424 936, 435377, 424 937

Abstract:

We propose here that endogenous stem/progenitor cells of the developing or adult nervous system be genetically modified in situ, to express therapeutically advantageous gene products. Furthermore, we propose here that endogenous or other exogenous stem cells or their progeny be genetically modified when appropriate to express advantageous gene products (and/or modified through culture techniques), and that, if exogenously derived, they be transplanted into the ventricular system of the patient nervous system, the germinal zone of the ventricular system, into postmitotic regions of the CNS or other organs.

US Patent:

20210378639, Dec 9, 2021

Filed:

Jun 4, 2021

Appl. No.:

17/338736

Inventors:

T. Que COLLINS - Los Angeles CA, US
Christopher Brian REID - Los Angeles CA, US

International Classification:

A61B 10/00
G01N 33/543

Abstract:

An exhaled breath condensate (EBC) collection device comprising two adjacent parts foldable together and apart from each other, a condensation zone to condense exhaled breath from a subject, the condensation zone being a third part provided between the two adjacent parts and connectable to cooling means arranged in each of the two parts being in cooling relationship with the condensation zone. There is also provided a method for detecting antigens or antibodies to the antigens, the method comprising collecting EBC from a subject using the EBC collection device, performing immunochromatographic testing (ICT) of the collected exhaled breath condensate, and interpreting the immunochromatographic testing results as follows: if the immunochromatographic testing results are positive, the antigens or antibodies to the antigens are detected, or if the immunochromatographic testing results are negative, the antigens or antibodies to the antigens are not detected.

US Patent:

20200048600, Feb 13, 2020

Filed:

Sep 24, 2019

Appl. No.:

16/579889

Inventors:

Christopher B. REID - Los Angeles CA, US
Melissa BRAGA - Monterey Park CA, US
Lilian N. SANTAMARIA - Los Angeles CA, US
Ashley N. WICKREMA - Los Angeles CA, US
Marinne D. WICKREMA - Los Angeles CA, US
Anthony HAO DINH - Garden Grove CA, US
Yaman EKSIOGLU - Atlanta GA, US
Mat HOANG HO - Birmingham AL, US

International Classification:

C12M 1/00
C12N 15/10
C12N 15/11
C12M 3/00
C12M 1/42

Abstract:

The claimed invention is directed towards a novel combination cell electroporation/cell culturing apparatus which can be termed a cell culture dish suitable for in vitro electroporation, and towards a device suitable for in vivo electroporation—both useful in methods suitable for the generation of developmentally-activated, pluripotent, pluripotent-like, multipotent, and/or self-renewing cells which are capable of beginning to differentiate in culture into a variety of cell types and capable of further differentiation in vivo. The claimed invention is also directed towards the generation of desirable, differentiating somatic cell populations transplantable to animals or patients, genetic modification of endogenous and exogenous cells, and the treatment of patients suffering from diseases that may be ameliorated by these methods. This invention also provides methods for preventing, treating, or retarding disease, for example, immunodeficiency virus (e.g. HIV-1, HIV-2, SIV, FIV, etc.) infection.

US Patent:

20190256813, Aug 22, 2019

Filed:

Oct 26, 2018

Appl. No.:

16/171420

Inventors:

Christopher B. REID - Los Angeles CA, US

International Classification:

C12M 3/06
C12M 1/00
C12N 5/00
C12M 1/42
C12N 13/00

Abstract:

A cell culture dish made of non media-permeable material and having a base and a plurality of separate juxtaposed side-by-side wells having common interior well walls preventing physical contact or movement of chemical factors between the separated cell or tissue cultures, the walls having different heights and defining an outer “surround” cell or tissue culture and one or more inner “center” cell or tissue cultures to enable contained cell or tissue communication between the well spaces, the wells configured to comprise two or more cell or tissue cultures, the wells permitting signal communication between the cells or tissues situated within said wells, and further comprising wall material, electrode contacts electrodes and/or electrode contacts, and well dimensions suitable for facilitating electroporation. The inventor observed 100% efficiency in cell reprogramming with protein electroporation-orders of magnitude above other reported methods.

US Patent:

20190008853, Jan 10, 2019

Filed:

Jul 18, 2018

Appl. No.:

16/039134

Inventors:

Christopher Brian REID - Los Angeles CA, US

International Classification:

A61K 31/496
A61K 45/06
A61K 31/327
A61K 31/4164
A61K 31/375
A61K 31/355
A61K 31/12
A61K 31/122
A61K 38/06
A61K 31/194
A61K 38/18
A61K 36/00

Abstract:

A method for reducing motility and number of cells, said method comprising contacting the cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the cells.

US Patent:

20160354370, Dec 8, 2016

Filed:

Aug 19, 2016

Appl. No.:

15/241308

Inventors:

Christopher Brian REID - Los Angeles CA, US

International Classification:

A61K 31/496
A61K 45/06
A61K 31/4164

Abstract:

Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.

US Patent:

20160002585, Jan 7, 2016

Filed:

Jan 29, 2014

Appl. No.:

14/764195

Inventors:

Christopher B. REID - Los Angeles CA, US
Keith NORRIS - Marina Del Rey CA, US
Taehoon CHO - Los Angeles CA, US
Victor CHABAN - Los Angeles CA, US

International Classification:

C12M 1/32
C12M 1/12
C12M 1/00
C12M 1/22

Abstract:

The present invention relates to a novel culturing apparatus (assembly) which can be termed a cell culture dish. More particularly, the present invention is a “combined cell culture dish” or “dish-in-dish” apparatus comprising at least one smaller cell culture dish fixedly positioned within a larger cell culture dish, and the number of such fixated cell culture dishes can include a multiple number of fixated cell culture dishes within one another, either concentric or eccentric, in any number of geometric shapes, and without limitation to the number of petri dishes included. An alternate embodiment of this invention can include a plurality of cell culture dishes juxtaposed side-by-side having common interior well walls, and the well walls may or may not be different in height depending on the application.

US Patent:

20140271923, Sep 18, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/815664

Inventors:

Christopher Brian Reid - Los Angeles CA, US

International Classification:

A61K 31/122
A61K 31/496
A61K 31/355
A61K 31/4164
A61K 31/12
A61K 31/375
A61K 38/06
A61K 45/06

US Classification:

424651, 514690, 514 219, 51425407, 514383, 514365, 514256, 514398, 5142362, 514314, 514154, 514311, 514 31, 514 77, 514 39, 514275, 51425308

Abstract:

Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.